Bevastim 100 mg/4 ml (IV Infusion)

100 mg vial: ৳ 18,560.00

Medicine Details

Metastatic colorectal cancer, with intravenous 5-fluorouracil-based chemotherapy for first-or second-line treatment
Metastatic colorectal cancer, with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for second-line treatment
Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first-line treatment of unresectable, locally advanced, recurrent or metastatic disease
Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy
Metastatic renal cell carcinoma with interferon alfa
Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease
Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is: (1) Platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan. (2) Platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Bevastim as a single agent

Recombinant humanized monoclonal IgG1 antibody
Binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF)
Produced in a mammalian cell (Chinese Hamster Ovary) expression system
Clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion

Recommended doses: 5 mg/kg or 10 mg/kg every 2 weeks for metastatic colorectal cancer (mCRC)
Recommended dose: 15 mg/kg every 3 weeks for Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC)
Recommended dose: 10 mg/kg every 2 weeks for Glioblastoma
Recommended dose: 10 mg/kg every 2 weeks for Metastatic Renal Cell Carcinoma (mRCC)
Recommended dose: 15 mg/kg every 3 weeks for Cervical Cancer
Recommended dose: 10mg/kg or 15 mg/kg every 2 weeks for Platinum-Resistant and Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

First infusion: Administer infusion over 90 minutes
Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated; administer all subsequent infusions over 30 minutes if first infusion over 60 minutes is tolerated
Use appropriate aseptic technique for preparation
Inspect visually for particulate matter and discoloration prior to administration
Dilute in a total volume of 100 ml of 0.9% Sodium Chloride injection, USP

No significant effect of Bevastim on the pharmacokinetics of irinotecan or its active metabolite SN38

Discontinue Bevastim if perforation or fistula occurs
Discontinue Bevastim for severe arterial thromboembolic events (ATE)
Discontinue Bevastim for life-threatening venous thromboembolic events (VTE)
Monitor blood pressure and treat hypertension
Discontinue Bevastim for posterior reversible encephalopathy syndrome (PRES)
Monitor urine protein and discontinue Bevastim for nephrotic syndrome
Stop Bevastim for severe infusion reactions
Advise females of potential risk to a fetus and the need for use of effective contraception
Advise females of the potential risk of ovarian failure

Safety, effectiveness and pharmacokinetic profile of Bevastim in pediatric patients have not been established
Bevastim is not approved for use in patients under the age of 18 years
Severe adverse events that occurred at a higher incidence in patients aged 65 years or older
Effect of Bevastim on overall survival was similar in elderly patients as compared to younger patients

Highest dose tested in humans (20 mg/kg IV) was associated with headache in nine out of 16 patients